Mast Therapeutics

We are a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. We have built our product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for sickle cell disease, a chronic, genetic disorder classified as a rare, or orphan, disease in the United States and European Union, and for heart failure, a condition with a high unmet need for innovative treatment options.
San Diego, US
Size (employees)
6 (est)-78%
Mast Therapeutics was founded in 1995 and is headquartered in San Diego, US

Mast Therapeutics Office Locations

Mast Therapeutics has office in San Diego
San Diego, US

Mast Therapeutics Metrics

Mast Therapeutics Summary

Market capitalization

$26.9 m

Closing share price

Mast Therapeutics's current market capitalization is $26.9 m.

Mast Therapeutics Financials

Mast Therapeutics's revenue is $2.1 m in FY, 2013
FY, 2013Y, 2014Y, 2015FY, 2016


$2.1 m$128 k

Revenue growth, %


Net Income

($208.6 m)($36.1 m)

Mast Therapeutics Market Value History

Mast Therapeutics Online Presence

Mast Therapeutics Company Life

You may also be interested in